The Promise of Peptide Therapeutics
PTG-100 PTG-200 PTG-300
June 18, 2021Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares More
Read the recently published manuscript on PN-943 here.

Welcome to Protagonist, a clinical-stage biopharmaceutical company poised to deliver life-changing therapies.

Clinical-stage new peptide entities addressing unmet medical needs

Learn More

Executive team with broad industry experience and success in drug development

Learn More

Collaborations with pharma giants and grassroots advocates

Learn More